[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587380":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":61,"collaborators":26,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":26,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1 - Standard of Care","ACTIVE_COMPARATOR","Participants on Arm 1 - SOC will be treated as per standard of care by their treating Oncologist. In most instances, it is anticipated participants will undergo a change in Systemic Therapy (ST) (including best supportive care). The ST will be at the discretion of the Oncologist and patient, according to best practices for the patient's diagnosis and clinical scenario. Patients can receive palliative radiotherapy for standard indications at any time.",[13,14],"Radiation: Stereotactic Body Radiation Therapy (SBRT)","Other: Systemic therapy",{"label":16,"type":17,"description":18,"interventionNames":19},"Arm 2 - Experimental","EXPERIMENTAL","Participants on Arm 2 - Experimental will receive standard of care SBRT to oligoprogressive sites according to institutional standards while remaining on the systemic treatment prescribed by the treating oncologist.",[13,14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","Stereotactic Body Radiation Therapy (SBRT)","SBRT will be delivered as per institutional standard.",[9,16],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Systemic therapy","Participants will receive Systemic Therapy. Participants in Arm 1 - SOC may change the Systemic Therapy throughout treatment. Participants in Arm 2 - Experimental will remain on the same Systemic Therapy throughout treatment.",[9,16],[32],{"name":33,"affiliation":34,"role":35},"Rachel Glicksman, MD","Princess Margaret Cancer Centre - University Health Network","PRINCIPAL_INVESTIGATOR",[37],{"name":33,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","416-946-4501","4961","rachel.glicksman@uhn.ca",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Princess Margaret Cancer Center","RECRUITING","Toronto","Ontario","M5G 2M9","Canada","CA",{"type":52,"coordinates":53},"Point",[54,55],-79.39864,43.70643,{"lat":55,"lon":54},[58],{"name":33,"role":38,"phone":59,"phoneExt":26,"email":60},"416-946-4483","rachel.glicksman@rmp.uhn.ca",{"type":62,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100587380","phase-2-stereotactic-body-radiotherapy-or-standard-of-care-for-prostate-oligoprogressive-cancer-100587380",false,"NCT06927635","Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer","Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer: a Randomized Phase II Trial","SECURE","Inclusion Criteria:\n\n* Age \\>18 years\n* Able to provide informed consent\n* Histologic diagnosis of prostate adenocarcinoma\n* Castrate Resistance Prostate Cancer\n* Radiographic evidence of \\\u003C10 sites of extra-cranial OP metastatic lesions\n* Receiving any line of ST for \\>3 months\n* All sites of OP disease are amenable to and can be safely treated with SBRT\n* ECOG performance status 0-3\n\nExclusion Criteria:\n\n* Evidence of spinal cord compression\n* Contraindication to radiotherapy","MALE","18 Years","100 Years",{"count":75,"type":76},75,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).",[82,83],"Castrate Resistance Prostate Cancer","OligoProgressive Metastatic Disease",[85,86],"systemic therapy","stereotactic body radiation therapy (SBRT)","2025-08-29",{"date":89,"type":90},"2025-09-05","ACTUAL",{"date":92,"type":90},"2025-07-08",{"date":94,"type":76},"2030-06",{"name":5,"class":6},1]